Dossier overview
3
research areas
2
references
3
handling notes
01
Mechanism of action
PE 22-28 is reported to inhibit TREK-1 (KCNK2) channel currents in heterologous expression systems and produce antidepressant-like effects in rodent behavioural tests, with longer persistence than the parent spadin peptide.
02
Research applications
- TREK-1 channel pharmacology
- Rodent forced-swim / tail-suspension behavioural models
- Cell-culture neurogenesis and synaptogenesis
Evidence at a glance
What's behind this profile
2 citations · 2015–2017
- Animal
- 1
- Review
- 1
Studies in rodents or other animal models.
Narrative or systematic reviews; no primary data.
Publication years
- 15
- 16
- 17
Counts are derived from the cited studies below. A study covering both in vivo and in vitro work is counted by its primary model. Sample size is reported in 0 of 2 citations. Findings remain model-specific and are not extrapolated to therapeutic use.
03
Study references
Each profile cites a minimum of two peer-reviewed sources, with model type and reported sample size where the source provides it. Findings are model-specific and must not be extrapolated to therapeutic use.
Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity
2017
Djillani A, Pietri M, Moreno S, Heurteaux C, Mazella J, Borsotto M · Frontiers in Pharmacology
- Model
- In vitro hTREK-1/HEK cells plus in vivo mouse behavioural antidepressant tests
- Sample
- Not reported in abstract
Reported PE 22-28 inhibited TREK-1 currents in hTREK-1/HEK cells and showed antidepressant-like activity in mouse models with longer persistence than spadin.
Targeting two-pore domain K+ channels TREK-1 and TASK-3 for the treatment of depression: a new therapeutic concept
2015
Borsotto M, Veyssiere J, Moha Ou Maati H, Devader C, Mazella J, Heurteaux C · British Journal of Pharmacology
- Model
- Narrative review (covers TREK-1 knockout mouse work)
- Sample
- N/A (review)
Reviews the rationale for TREK-1 / TASK-3 inhibition as an antidepressant strategy, including the spadin lineage that PE 22-28 was developed from.
Evidence caveats
- No controlled human trials indexed on PubMed at time of writing.
- All published primary evidence originates from the Mazella / Borsotto group at IPMC-CNRS; independent replication is limited.
- Findings are model-specific (rodent / in vitro) and are not extrapolated to therapeutic use.
04
Storage and handling
Typically stored in a cool, dry environment under controlled laboratory conditions per supplier documentation.
- Use supplier documentation for batch-specific handling.
- Limit repeated cycles during research inventory handling.
- Document date and storage condition where applicable.